# US 2016/0257985 A1 · Degradable adaptors for background reduction

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0257985 A1
- Document ID: US20160257985A1
- Status: Published application
- Kind: A1
- Application number: 15/035,951
- Filed: 2014-11-18
- Published: 2016-09-08
- Earliest claimed: 2013-11-18
- Assignees: Rubicon Genomics, Inc.
- Applicants: Rubicon Genomics, Inc.
- Inventors: Emmanuel Kamberov; John Langmore; Tim Tesmer
- Web page: https://patentgrep.com/patent/US20160257985A1

## CPC

- C12P 19/34: Polynucleotides, e.g. nucleic acids, oligoribonucleotides
- C12Q 1/6806: Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay (C12Q1/6804 takes precedence)
- C12Q 1/6848: characterised by the means for preventing contamination or increasing the specificity or sensitivity of an amplification reaction
- C12P: FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE {(brewing of beer C12C; producing vinegar C12J; producing specific peptides or proteins C07K; producing enzymes C12N9/00; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; measuring or testing processes involving enzymes or microorganisms C12Q; measuring or testing processes involving nucleic acid amplification reactions C12Q1/6844; fermentation processes to form a food composition, A21 or A23; compounds in general, see the relevant compound class, e.g. C01, C07)}
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The present disclosure provides systems, processes, articles of manufacture, and compositions that relate to the use of degradable adaptors for background reduction in various nucleic acid manipulations. In particular, adaptors are provided that can be degraded to an extent that the degradation products are incapable or are substantially incapable from participating in subsequent reactions, such as ligation, primer extension, amplification, and sequencing reactions.

## Claims

### Claim 1

A method for processing a nucleic acid having at least one cleavable base, comprising:
(a) creating an abasic site at the at least one cleavable base;
(b) creating a nick in the backbone of the nucleic acid at the abasic site; and
(c) removing at least one nucleotide adjacent to the nick.

### Claim 2 (depends on 1)

The method of claim 1, wherein the nucleic acid comprises a degradable adaptor.

### Claim 3 (depends on 2)

The method of claim 2, wherein the degradable adaptor is a partially double-stranded oligonucleotide adaptor, a double-stranded oligonucleotide adaptor, or a stem-loop oligonucleotide adaptor.

### Claim 4 (depends on 3)

The method of claim 3, wherein the stem-loop oligonucleotide adaptor comprises:
(a) a 5′ segment comprising at least one cleavable base;
(b) an intermediate segment coupled to the 3′-end of the 5′ segment; and
(c) a 3′ segment coupled to the 3′-end of the intermediate segment, wherein the 5′ segment and 3′ segment are at least 80% complementary.

### Claim 5 (depends on 4)

The method of claim 4, wherein the 3′ segment does not contain a cleavable base.

### Claim 6 (depends on 4)

The method of claim 4, wherein the intermediate segment comprises at least one cleavable base.

### Claim 7 (depends on 4)

The method of claim 4, wherein the 5′ segment and the intermediate segment of the stem-loop oligonucleotide adaptor comprises a cleavable base every 3-6 bases.

### Claim 8 (depends on 1, 4, 5, 6, 7)

The method of any one of claims 1 and 4-7, wherein the cleavable base is deoxyuridine.

### Claim 9 (depends on 1)

The method of claim 1, wherein creating an abasic site at the at least one cleavable base comprises treating the nucleic acid having at least one cleavable base with uracil-DNA glycosylase.

### Claim 10 (depends on 1)

The method of claim 1, wherein creating a nick at the abasic site comprises treating the nucleic acid of step (a) with an apurinic/apyrimidinic endonuclease.

### Claim 11 (depends on 1)

The method of claim 1, wherein removing at least one nucleotide adjacent to the nick comprises treating the nucleic acid of step (b) with an exonuclease.

### Claim 12 (depends on 10)

The method of claim 10, wherein the apurinic/apyrimidinic endonuclease is APE 1.

### Claim 13 (depends on 11)

The method of claim 11, wherein the exonuclease is Exonuclease I.

### Claim 14

A method for preparing a nucleic acid molecule, comprising:
(a) providing a double stranded nucleic acid molecule;
(b) ligating a 3′ end of degradable adaptor comprising at least one cleavable base to a 5′ end of the double stranded nucleic acid molecule to produce an oligonucleotide-attached nucleic acid molecule;
(c) creating an abasic site at the at least one cleavable base;
(d) creating a nick at the abasic site; and
(e) removing at least one nucleotide adjacent to the nick.

### Claim 15 (depends on 14)

The method of claim 14, wherein the degradable adaptor is a partially double-stranded oligonucleotide adaptor, a double-stranded oligonucleotide adaptor, or a stem-loop oligonucleotide adaptor.

### Claim 16 (depends on 15)

The method of claim 15, wherein the stem-loop oligonucleotide adaptor comprises:
(i) a 5′ segment comprising at least one cleavable base;
(ii) an intermediate segment coupled to a 3′-end of the 5′ segment; and
(iii) a 3′ segment coupled to a 3′-end of the intermediate segment, wherein the 5′ segment and the 3′ segment are at least 80% complementary.

### Claim 17 (depends on 16)

The method of claim 16, wherein the 3′ segment does not contain a cleavable base.

### Claim 18 (depends on 15)

The method of claim 15, wherein the intermediate segment comprises at least one cleavable base.

### Claim 19 (depends on 18)

The method of claim 18, wherein the 5′ segment and the intermediate segment of the stem-loop oligonucleotide adaptor comprises a cleavable base every 3-6 bases.

### Claim 20 (depends on 14, 16, 17, 18, 19)

The method of any one of claims 14 and 16-19, wherein the cleavable base is deoxyuridine.

### Claim 21 (depends on 14)

The method of claim 14, wherein the ligating produces a nick in the oligonucleotide-attached nucleic acid molecule.

### Claim 22 (depends on 14)

The method of claim 14, wherein the double stranded nucleic acid molecule is a double stranded DNA molecule.

### Claim 23 (depends on 14)

The method of claim 14, further comprising amplification of at least part of the oligonucleotide-attached nucleic acid molecule.

### Claim 24 (depends on 23)

The method of claim 23, wherein the amplification comprises polymerase chain reaction.

### Claim 25 (depends on 16)

The method of claim 16, wherein the stem-loop oligonucleotide comprises a known sequence.

### Claim 26 (depends on 14)

The method of claim 14, wherein the oligonucleotide-attached nucleic acid molecule is further modified.

### Claim 27 (depends on 26)

The method of claim 26, wherein the further modification comprises cloning.

### Claim 28 (depends on 27)

The method of claim 27, wherein cloning is further defined as comprising incorporation of the modified molecule into a vector, said incorporation occurring at ends in the modified molecule generated by endonuclease cleavage within the inverted repeat.

### Claim 29 (depends on 14)

The method of claim 14, wherein the method is further defined as occurring in a single suitable solution, wherein the process occurs in the absence of exogenous manipulation.

### Claim 30 (depends on 14)

The method of claim 14, wherein the steps of the method are performed sequentially.

### Claim 31 (depends on 29)

The method of claim 29, wherein the solution comprises one or more of the following: ligase, Uracil-DNA Glycosylase, an apurinic/apyrimidinic endonuclease, an exonuclease, ATP, and dNTPs.

### Claim 32 (depends on 14)

The method of claim 14, wherein the oligonucleotide-attached nucleic acid molecule is immobilized on a solid support.

### Claim 33 (depends on 32)

The method of claim 32, wherein the molecule is immobilized non-covalently.

### Claim 34

A kit comprising:
(a) a nucleic acid comprising at least one cleavable base;
(b) a uracil-DNA glycosylase;
(c) an apurinic/apyrimidinic endonuclease; and
(d) an exonuclease.

### Claim 35 (depends on 34)

The kit of claim 34, wherein the nucleic acid comprises a degradable adaptor.

### Claim 36 (depends on 35)

The kit of claim 35, wherein the degradable adaptor is a partially double-stranded oligonucleotide adaptor, a double-stranded oligonucleotide adaptor, or a stem-loop oligonucleotide adaptor.

### Claim 37 (depends on 36)

The kit of claim 36, wherein the stem-loop oligonucleotide adaptor comprises:
(a) a 5′ segment comprising at least one cleavable base;
(b) an intermediate segment coupled to the 3′-end of the 5′ segment; and
(c) a 3′ segment coupled to the 3′-end of the intermediate segment, wherein the 5′ segment and 3′ segment are at least 80% complementary.

### Claim 38 (depends on 37)

The kit of claim 37, wherein the 3′ segment does not contain a cleavable base.

### Claim 39 (depends on 37)

The kit of claim 37, wherein the intermediate segment comprises at least one cleavable base.

### Claim 40 (depends on 39)

The kit of claim 39, wherein the 5′ segment and the intermediate segment of the stem-loop oligonucleotide adaptor comprises a cleavable base every 3-6 bases.

### Claim 41 (depends on 34, 37, 38, 39, 40)

The kit of any one of claims 34 and 37-40, wherein the cleavable base is deoxyuridine.

### Claim 42 (depends on 34)

The kit of claim 34, wherein the apurinic/apyrimidinic endonuclease is APE 1.

### Claim 43 (depends on 34)

The kit of claim 34, wherein the exonuclease is Exonuclease I.
